Loading
Sentiment · FY2026 Q2
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $6.44B | +10.7% | $1.41 | -52.7% | 62.0% | 25.8% | 8.5% | $1.67B |
| FY2025 Q1 | $5.87B | +11.9% | $1.69 | -17.6% | 62.7% | 20.1% | 11.1% | $127M |
| FY2025 Q2 | $6.02B | +11.1% | $2.29 | +7.0% | 62.3% | 22.6% | 14.7% | $928M |
| FY2025 Q3 | $6.06B | +10.2% | $2.22 | +2.8% | 63.6% | 18.7% | 14.2% | $1.35B |
| FY2025 Q4 | $7.17B | +11.4% | $2.20 | +56.0% | 65.2% | 27.3% | 11.8% | $1.88B |
| FY2026 Q1 | $6.02B | +2.6% | $1.93 | +14.2% | 63.3% | 15.5% | 12.4% | $415M |
| FY2026 Q2 | $6.59B | +9.4% | $3.30 | +44.1% | 68.3% | 25.2% | 19.4% | — |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Larry Biegelsen | Wells Fargo | 14 (14%) |
| Ryan Zimmerman | BTIG | 12 (8%) |
| Travis Steed | Bank of America |
Organic growth decelerated sharply to 2.4% as a cyber incident disrupted Q1 revenue and operations, compressing adjusted EPS to $2.60, down 8.5%, with adjusted gross margin declining 190 basis points to 63.6%. Despite the disruption, full-year guidance was maintained at 8-9.5% organic growth and $14.90-$15.10 EPS, reflecting management's confidence in the recovery trajectory. Mako delivered record Q1 installations globally while the AVS acquisition expanded the peripheral vascular platform and tariff plus input cost headwinds continued pressuring margins.
Revenue Growth | Innovation & R&D | Demand | Product Launch | M&A | Competitive Dynamics | Margin | Guidance Reliability | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 9 | 6 | 5 | 5 | 10 | 1 | 2 | 4 |
| 2025Q1 | 4 | 2 | 6 | 3 | 3 | 2 | 5 | 2 |
| 2025Q2 | 7 | 11 | 8 | 6 | 2 | 6 | 3 | 3 |
| 2025Q3 | 9 | 2 | 3 | 5 | 5 | 4 | 4 | 1 |
| 2025Q4 | 8 | 9 | 5 | 6 | 4 | 7 | 5 | 3 |
| 2026Q1 | 6 | 4 | 6 | 7 | 6 | 6 | 3 | 3 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9 | 4 | 7 | 9 | 8 | 6 |
| Innovation & R&D | 6 | 2 | 11 | 2 | 9 | 4 |
| Demand | 5 | 6 | 8 | 3 | 5 | 6 |
| Product Launch | 5 | 3 | 6 | 5 | 6 | 7 |
| M&A | 10 | 3 | 2 | 5 | 4 | 6 |
| Competitive Dynamics | 1 | 2 | 6 | 4 | 7 | 6 |
| Margin | 2 | 5 | 3 | 4 | 5 | 3 |
| Guidance Reliability | 4 | 2 | 3 | 1 | 3 | 3 |
| Vijay Kumar | Evercore ISI | 12 (0%) |
| Robbie Marcus | JPMorgan | 12 (0%) |
| Mike Matson | Needham | 11 (0%) |
| Caitlin Cronin | Canaccord Genuity | 10 (0%) |
| Matt Miksic | Barclays | 10 (0%) |
| Joanne Wuensch | Citigroup | 9 (0%) |
| Pito Chickering | Deutsche Bank | 8 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Wells Fargo | 1 | 14 (14%) |
| JPMorgan | 2 | 14 (0%) |
| Evercore ISI | 2 | 13 (0%) |
| Bank of America | 1 | 12 (8%) |
| BTIG | 1 | 12 (8%) |
| Needham | 1 | 11 (0%) |
| UBS | 2 | 11 (0%) |
| Piper Sandler | 3 | 11 (9%) |
What SYK and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“Adjusted other income and expense of $97 million was $24 million higher than 2025 due to higher interest expense from debt issued in 2025 to help fund the acquisition of Inari”
Stryker's 2025 Inari acquisition, funded partly by new debt, is roughly a year in; management says sales-force attrition is largely behind it and it is now a growth platform in vascular.
“On the M&A front, we recently announced the agreement to acquire Amplitude Vascular Systems that we expect to close in the second quarter.”
Stryker is acquiring Amplitude Vascular Systems (IVL technology) to expand its peripheral vascular and broader cardiovascular presence, with a possible product launch as early as late 2026.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
SYK Stryker Corporation | 4 | +2.6% | |
| ABT Abbott Laboratories | 6 | +7.8% | |
| ALGN Align Technology | 6 | +6.2% | |
| BSX Boston Scientific | 6 | +11.6% | |
| DXCM DexCom | 9 | +15.1% | |
| EW Edwards Lifesciences | 9 | +16.7% | |
| MDT Medtronic | 7 | +8.8% | |
| PODD Insulet Corporation | 8 | +33.9% | |
| STE Steris | 7 | +7.3% | |
| ZBH Zimmer Biomet | 9 | +9.3% |